<p>Safety and Tolerability of PCSK9 Inhibitors: Current Insights</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

Published:2020-12 Issue: Volume:Volume 12 Page:191-202
ISSN:1179-1438
Container-title:Clinical Pharmacology: Advances and Applications
language:en
Short-container-title:CPAA

Author:

Kosmas Constantine E,Skavdis Andreas,Sourlas Andreas,Papakonstantinou Evangelia J,Peña Genao Edilberto,Echavarria Uceta Rogers,Guzman Eliscer

Publisher

Informa UK Limited

Subject

Pharmacology (medical)

Reference73 articles.

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736–1788.

2. Molecular Pathways Underlying Cholesterol Homeostasis

3. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

4. The effect of dyslipidemic drugs on mortality: A meta-analysis

5. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels – experimental and clinical approaches with lipid-lowering agents

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypolipidemic activity of phytochemical combinations: A mechanistic review of preclinical and clinical studies;Food Chemistry;2024-11

2. Unraveling the Nexus Between Ambient Air Pollutants and Cardiovascular Morbidity: Mechanistic Insights and Therapeutic Horizons;Cureus;2024-09-04

3. Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)–A discrete choice experiment;Heliyon;2024-08

4. Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes;World Journal of Cardiology;2024-07-26

5. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3